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5. LC-MS/MS  
Abstract  
Aims: The purpose of this study was to 
develop high-sensitivity analytical methods 
for the determination of lansoprazole and 
5-hydroxy lansoprazole, glibenclamide and 
warfarin, and metoprolol and α-hydroxyl 
metoprolol in human plasma using high 
performance liquid chromatography – triple 




Methods: Lansoprazole and 5-hydroxy lansoprazole were extracted 
from plasma samples by deproteinization using methanol. 
Glibenclamide and warfarin were extracted from plasma samples by 
solid phase extraction using an OASIS HLB cartridge.  Metoprolol 
and α-hydroxyl metoprolol were extracted from plasma samples by 
liquid-liquid extraction using tert-butyl methyl ether. 
Results: The quantification range of lansoprazole and 5-hydroxy 
lansoprazole was 10 to 10,000 pg/mL.  Lansoprazole and 5-hydroxy 
lansoprazole were monitored at m/z 370.4⇀136.0 and 386.3⇀135.1, 
respectively. The quantification range of glibenclamide was 1 to 
1,000 pg/mL, and that of warfarin was 50 to 50,000 pg/mL. 
Glibenclamide and warfarin were monitored at m/z 494.2⇀368.9 and 
309.0⇀163.3, respectively. The quantification range of metoprolol and 
α-hydroxyl metoprolol was 0.1 to 50 ng/mL.  Metoprolol and 
α-hydroxyl metoprolol were monitored at m/z 269.0⇀116.0 and 
285.1⇀116.1, respectively. 
Conclusions: These established analytical methods could be useful in 
micro-dose clinical studies and the concentration of these drugs and 
their metabolites in human plasma could be evaluated after oral 
administration of these drugs. 
 
Background and Aims 
In the development of pharmaceutical products, the 
determination of drug concentrations in biological 
samples is important to assess the safety from the view 
of health effect by drugs． Recently, a high-sensitivity 
analytical method has become necessary to evaluate drug 
disposition.  In addition, the measurement of a drug and 
its metabolites in biological samples is necessary to 
develop pharmaceutical products.  It is also necessary to 







Lansoprazole, glibenclamide, warfarin, and 
metoprolol are metabolized by CYP2C19, CYP2C9, 
CYP2C9, and CYP2D6, respectively
 (1, 2)
.  These drugs 
are commercially available as the following medicines: 
Lansoprazole, one of the proton pump inhibitors to 
control production of acid in the stomach, and 5-hydroxy 
lansoprazole, an active metabolite of lansoprazole 
(3, 4)
.  
Glibenclamide is an antidiabetic drug
 (5)
.  Warfarin is an 
anticoagulant drug
 (6)
.  Metoprolol, an adrenergic effect 
blocker and can selectively intercept beta 1 receptor, 
which is used for control of hypertension and arrhythmia 
(7)
.  Also α-hydroxy metoprolol is a major metabolite of 
metoprolol
 (7)
.  In addition, these compounds are known 
as substrates which can interact or inhibit CYP enzymes 
easily, and affect drug metabolism
 (1, 2)
. 
These compounds are assumed to be administered 
with new drugs with consideration to drug-drug 
interactions, therefore it is important to analyze these 
compounds using high sensitivity.  However, 
high-sensitivity analytical methods for these drugs have 
not been reported.  Therefore, we wanted to establish 
high-sensitivity analytical methods for these compounds. 
In this study, the limits of quantification of drugs 
(chemical structures shown in Figure 1) added to human 
plasma and their metabolites were assessed by 
LC-MS/MS analytical methods.  The lower limits of 
quantification (LLOQ) that are the same or exceed the 
necessary sensitivity for the assessment of drug safety 
were developed.  Different sample preparation methods 
were developed for each drug.  After establishing the 
analytical method of each drug, we examined whether 
the method can be used for the assessment of drug safety 




Lansoprazole and 5-hydroxy lansoprazole 
potassium salt were purchased from Toronto Research 
Chemicals Inc. (North York, ON, Canada).  Prednisolon 
(internal standard for lansoprazole and 5-hydroxy 
lansoprazole) and cimetidine (internal standard of 
metoprolol and α-hydroxy metoprolol) were purchased 
from Wako Pure Chemicals Industries (Osaka, Japan).  
Glibenclamide, warfarin, and (±)-metoprolol (±)-tartrate 
salt were purchased from Sigma-Aidrich Co. LCC (St. 
Louis, MO, USA).  Buspirone hydrochloride (internal 
standard of dextromethorophan and dextrophan, 
glibenclamide and warfarin) was purchased from LKT 
laboratories Inc. (St. Paul, MN, USA).  α-Hydroxy 
metoprolol was kindly supplied by Tokyo University. 
 
Blank matrix 
Blank human plasma (anticoagulant: heparin 
sodium) was collected from 6 healthy volunteers and 
stored at -20°C.  This study was approved by the 
Human Ethical Review Board in Shin Nippon 




A Shimadzu 10A series liquid chromatography 
(Shimadzu Co., Ltd., Kyoto, Japan) and an API5000 
triple quadrupole mass spectrometer (AB Sciex, 
Framingham, MA, USA) were used for LC-MS/MS 
analysis and operated by Analyst software version 1.4 
(AB Sciex, Framingham, MA, USA). 
 
Preparation of standard solutions 
Lansoprazole and 5-hydroxy lansoprazole were 
dissolved in methanol and diluted to 0.1, 0.2, 1, 2, 10, 20, 
and 100 ng/mL.  Prednisolon (internal standard for 
lansoprazole and 5-hydroxy lansoprazole analysis) was 
dissolved in methanol and diluted to 10 ng/mL.  To 
prepare calibration and quality control (QC) samples, 10 
μL of standard solution was added to 100 μL of blank 
human plasma.  Calibration samples were prepared at 
10, 20, 100, 200, 1,000, 2,000 and 10,000 pg/mL in 
lansoprazole and 5-hydroxy lansoprazole.  QC samples 
of lansoprazole and 5-hydroxy lansoprazole at 20, 400, 
8,000 pg/mL were prepared. 
Glibenclamide was dissolved in methanol and 
diluted to 0.01, 0.02, 0.1, 0.2, 1, 2, and 10 ng/mL.  
Warfarin was dissolved in methanol and diluted to 0.5, 1, 
5, 10, 50, 100, and 500 ng/mL.  Buspirone (internal 
standard for glibenclamide and warfarin analysis) was 
dissolved in methanol and diluted to 1 ng/mL.  To 
prepare calibration and QC samples, 20 μL of standard 
solution was added to 200 μL of blank human plasma.  
Calibration samples of glibenclamide at 1, 2, 10, 20, 100, 
200, and 1,000 pg/mL, and those of warfarin at 50, 100, 
500, 1,000, 5,000, 10,000, and 50,000 pg/mL were 
prepared.  QC samples of glibenclamide at 2, 40, and 
800 pg/mL and those of warfarin at 100, 2,000, and 
40,000 pg/mL were prepared.  
Metoprolol and α-hydroxy metoprolol were 
dissolved in methanol and diluted to 1, 2, 10, 20, 100, 
200, and 500 ng/mL.  Cimetidine (internal standard for 
metoprolol and α-hydroxy metoprolol analysis) was 
dissolved in methanol and diluted to 1 ng/mL.  To 
prepare calibration and QC samples, 10 μL of standard 
solution was added to 100 μL of blank human plasma.  
Calibration samples of metoprolol and α-hydroxy 
metoprolol at 0.1, 0.2, 1, 2, 10, 20, and 50 ng/mL and 
QC samples at 0.2, 2, 40 ng/mL were prepared. 
 
Sample preparation 
Lansoprazole and 5-hydroxy lansoprazole 
Internal standard solution (30 μL) was added to 110 
μL of each calibration standard and QC sample and 
mixed well using a vortex mixer.  Internal standard 
solution (30 μL) and 10 μL of methanol were added to 
100 μL of measurement samples (clinical sample) and 
the resultant solutions were mixed well.  Methanol (30 
μL) was added to 110 μL of blank plasma and mixed 
well.  To these solutions, 500 μL of methanol was 
added and the resultant solutions were mixed well and 
centrifuged (10,000 rpm, 2 minutes, 4°C).  The 
supernatant was collected and evaporated to dryness 
under a stream of nitrogen at 40°C or below.  To 
reconstitute the residue, 50 μL of methanol and 50 μL of 
ultrapure water were added. 
 
Glibenclamide and warfarin 
Internal standard solution (10 μL) was added to 220 
μL of each calibration standard and QC sample and 




μL of methanol were added to 200 μL of measurement 
samples and mixed well.  Methanol (10 μL) was added 
to 220 μL of blank plasma and mixed well. 
  To these solutions, 400 μL of ultrapure water was 
added and mixed well then loaded into a solid phase 
extraction cartridge (OASIS HLB 1cc/30 mg) that was 
preconditioned with 1 mL of acetonitrile and 1 mL of 
ultrapure water.  The cartridge was washed twice with 
500 μL of ultrapure water.  Samples were eluted with 
500 µL of acetonitrile.  Eluate was evaporated to 
dryness under a stream of nitrogen (setting: 40°C or 
below).  To reconstitute the residue, 20 μL of 
acetonitrile and 80 μL of ultrapure water were added. 
 
Metoprolol and α-hydroxy metoprolol 
Internal standard solution (10 μL) was added to 110 
μL of each calibration standard and QC sample and 
mixed well.  Internal standard solution (10 μL) and 10 
μL of methanol were added to 100 μL of measurement 
samples and mixed well.  Methanol (10 μL) was added 
to 110 μL of blank plasma and mixed well.  To these 
solutions, 100 μL of 25% ammonia water and 1,500 μL 
of ultrapure water were added and mixed well, then 5 mL 
of tert-butyl methyl ether was added and the resultant 
solutions were shaken for 10 minutes.  The organic 
layer was collected in a dry-ice/acetone bath.  Eluate 
was evaporated to dryness under a stream of nitrogen at 
40°C or below.  To reconstitute the residue, 40 μL of 
acetonitrile and 60 μL of ultrapure water were added. 
 
Analysis Methods 
Analytical conditions for lansoprazole and 5-hydroxy 
lansoprazole 
The chromatographic separations were performed 
using a CAPCELL PAK C18 MG-II (2.0 mm i.d. × 50 
mm, 3 µm, Shiseido Co., Ltd., Tokyo, Japan) as the 
analytical column and an Inertsil ODS-3 (3.0 mm i.d. × 
10 mm, 3 μm, GL Sciences Inc., Tokyo, Japan) as the 
guard column.  Elution was carried out using an 
acetonitrile and 20 mmol/L ammonium acetate buffer 
(pH 7.6) solution (50:50, v/v%) as mobile phase.  The 
flow rate was 0.3 mL/min, column oven was set at 40°C, 
and inside the autosampler was kept at 4°C.  The 
injection volume was 20 μL and the analytical run time 
was 7 minutes.  The mass spectrometer was operated in 
electrospray ionization (ESI) positive ion mode and 
lansoprazole and 5-hydroxy lansoprazole were quantified 
using multiple reactions monitoring (MRM) mode.  
TurboIonSpray was used at 400°C.  Optimized 
precursor to product ion transitions monitored at m/z 
370.4⇀136.0, 386.3⇀135.1, and 361.5⇀147.2 were used 
for quantification of lansoprazole, 5-hydroxy lansoprazol, 
and internal standard, respectively. 
 
Analytical conditions of glibenclamide and warfarin 
The chromatographic separations were performed 
using a Cadenza CD-C18 (2.0 mm i.d. × 150 mm, 3 μm, 
Imtakt Corporation, Kyoto, Japan) as the analytical 
column and an Inertsil ODS-3 (3.0 mm i.d. × 10 mm, 3 
μm, GL Sciences Inc, Tokyo, Japan) as the guard column.  
Elution was carried out using an acetonitrile and 20 
mmol/L ammonium acetate buffer (pH 7.4) solution 
(50:50, v/v%) as mobile phase.  The flow rate was 0.3 
mL/min, column oven was set at 40°C, and inside the 
autosampler was kept at 4°C.  The injection volume 
was 20 μL and analytical run time was 9 minutes.  The 
mass spectrometer was operated in ESI positive ion 
mode and gilbenclamide and warfarin were quantified 
using MRM mode.  TurboIonSpray was used at 400°C.  
Optimized precursor to product ion transitions monitored 
at m/z 494.2⇀368.9, 309.0⇀163.3, and 386.6⇀122.0 
were used for quantification of glibenclamide, warfarin, 
and internal standard, respectively. 
 
Analytical conditions of metoprolol and α-hydroxy 
metoprolol 
The chromatographic separations were performed 
using a CAPCELL PAK CR 1:4 (2.0 mm i.d. ×50 mm, 
Shiseido Co., Ltd., Tokyo, Japan) as the analytical 
column.  Elution was carried out using an acetonitrile 
and 20 mmol/L ammonium acetate buffer solution (50:50, 
v/v%) as mobile phase.  The flow rate was 0.3 mL/min, 
column oven was set at 35°C, and inside the autosampler 
was kept at 4°C.  Injection volume was 20 μL and 
analytical run time was 5 minutes.  The mass 
spectrometer was operated in ESI positive ion mode and 
metoprolol and α-hydroxy metoprolol were quantified 
using MRM mode.  TurboIonSpray was used at 400°C.  
Optimized precursor to product ion transitions monitored 
at m/z 269.0⇀116.0, 285.1⇀116.1, and 253.4⇀159.2 
were used for quantification of metoprolol, α-hydroxy 
metoprolol, and internal standard, respectively. 
 
Results and Discussion 
Validation of lansoprazole and its metabolites analysis 
We examined whether there were interfering peaks 
to lansoprazole, 5-hydroxy lansoprazole, or internal 
standard in chromatograms of samples prepared using 
blank plasma obtained from 6 individuals (Figure 2).  
No interfering peaks of internal standard or carry-over 
were observed.  The linearity of a quantification range 
of lansoprazole and 5-hydroxy lansoprazole from 10 to 
10,000 pg/mL was examined.  Accuracy (relative error 
(RE)) values for different weighting factors that met the 
acceptance criteria (RE within ±20% at the LLOQ and 
within ±15% at other concentrations) were compared, 
and weighting factor of 1/X
2
, having the smallest RE, 
was selected as the calibration curve.  Precision 
(coefficient of variation (CV)) and RE in the 
reproducibility test met the acceptance criteria (CV not 
exceeding 20% at the LLOQ and not exceeding 15% at 
other concentrations, RE within ±20% at the LLOQ and 
within ±15% at other concentrations) and are shown in 
Tables I and II.  The results of the linearity and 
within-run accuracy and precision tests determined the 
lower concentration (10 pg/mL) and higher concentration 
(10,000 pg/mL) in a calibration curve that met the 
acceptance criteria (CV not exceeding 20% at the LLOQ 
and not exceeding 15% at other concentrations, RE 
within ±20% at the LLOQ and within ±15% at other 
concentrations) as LLOQ and upper limit of quantitation 
(ULOQ), respectively.  The LLOQ of lansoprazole 




analytical methods was 1 or 2 ng/mL
(8, 9)
.  The 
developed method for lansoprazole in the present study 
showed higher sensitivity than previously reported 
methods.  The recovery and matrix effects of 
lansoprazole and 5-hydroxy lansoprazole were similar in 
each sample analysis, which confirmed both compounds 
could be consistently quantified. Lansoprazole and 
5-hydroxy lansoprazole in 10- and 100-fold diluted 
solutions with blank plasma met the acceptance criteria 
(CV not exceeding 15%, RE within ±15%) for dilution 
integrity.  Lansoprazole and 5-hydroxy lansoprazole in 
sample extracts were confirmed to be stable for 72 hours 
when stored at 4°C in an autosampler. Lansoprazole and 
5-hydroxy lansoprazole in plasma were confirmed to be 
stable at room temperature for 24 hours, frozen at −80°C 
for 254 days, and for three freeze (−80°C) and thaw 
cycles.  The 5-hydroxy lansoprazole standard solutions 
and internal standard solution were stable at 4°C for 98 
days but lansoprazole standard solutions did not meet the 
acceptance criteria (CV not exceeding 15%, RE within 
±15%).  The additional stability test confirmed that 
standard solutions, which were stored at 4°C for 8 days, 
met the acceptance criteria (CV not exceeding 15%, RE 
within ±15%) for stability, therefore, the expiration of 
standard solution and internal standard solution was set 
at 8 days and 98 days, respectively. 
 
Validation of glibenclamide and warfarin analysis 
We examined whether there were interfering peaks 
to glibenclamide, warfarin, or internal standard in 
chromatograms of samples prepared using blank plasma 
obtained from 6 individuals (Figure 3).  No interfering 
peaks of internal standard or carry-over were observed.  
Linearity for calibration curves of glibenclamide in 
plasma in a range from 1 to 1,000 pg/mL and that of 
warfarin in a plasma in a range from 50 to 50,000 pg/mL 
were tested and the weighting factor of 1/X
2
, which met 
the acceptance criteria with the smallest accuracy value 
(relative error: RE) was selected.  Precision (CV) and 
RE in the reproducibility test met the acceptance criteria 
(CV not exceeding 20% at the LLOQ but not exceeding 
15% at other concentrations, RE within ±20% at the 
LLOQ and within ±15% at other concentrations) and are 
shown in Tables III and IV.  The results of the linearity, 
within-run accuracy, and precision tests determined the 
lower concentration (Glibenclamide: 1 pg/mL and 
Warfarin: 50 pg/mL) and higher concentration 
(Glibenclamide: 1,000 pg/mL and Warfarin: 50,000 
pg/mL) in calibration curves that met the acceptance 
criteria as LLOQ and ULOQ, respectively.  The LLOQ 
of glibenclamide and warfarin concentrations reported by 
the previously published analytical methods were 0.25 or 
20 ng/mL
(10, 11)
 and 0.5 ng/mL
(12)
, respectively.  The 
developed method for glibenclamide and warfarin in the 
present study had higher sensitivity than previously 
reported methods.   The recovery and matrix effects of 
glibenclamide and warfarin were similar in each sample 
analysis, which confirmed both compounds could be 
appropriately quantified.  Glibenclamide and warfarin 
in 10- and 100-fold diluted solutions with blank plasma 
met the acceptance criteria (CV not exceeding 15%, RE 
within ±15%) for dilution integrity.  Glibenclamide and 
warfarin in sample extracts were stable for 24 and 12 
hours, respectively.  Glibenclamide and warfarin were 
stable at 4°C in an autosampler, frozen at −80°C for 304 
days, and for three freeze (−80°C) and thaw cycles in 
plasma.  Warfarin and glibenclamide standard solutions 
were stable at 4°C for 3 months. 
 
Validation of metoprolol and its metabolites analysis 
We examined whether there were interfering peaks 
to metoprolol, α-hydroxy metoprolol, or internal standard 
in chromatograms of samples prepared using blank 
plasma obtained from 6 individuals (Figure 4).  No 
interfering peaks of internal standard or carry-over were 
observed.  The linearity of a quantification range from 
0.1 to 50 ng/mL in the analysis of metoprolol and 
α-hydroxy metoprolol was examined.  Accuracy (RE) 
values in weighting factors that met the acceptance 
criteria were compared and 1/X
2
, having the smallest RE 
at the low concentration, was selected as the calibration 
curve.  Precision (CV) and RE in the reproducibility 
test met the acceptance criteria (CV not exceeding 20% 
at the LLOQ but not exceeding 15% at other 
concentrations, RE within ±20% at the LLOQ and within 
±15% at other concentrations) and are shown in Tables V 
and VI.  The results of the linearity test and within-run 
accuracy and precision test determined the lower 
concentration (0.1 ng/mL) and higher concentration (50 
ng/mL) in calibration curves that met the acceptance 
criteria as LLOQ and ULOQ, respectively.  The LLOQ 
of metoprolol concentration reported by the previously 
published analyses was 0.1 or 3 ng/mL
(13, 14)
.  The 
LLOQ of our developed analytical method for 
metoprolol in the present study was comparable to that of 
reported methods, however we were not able to establish 
a higher-sensitivity analytical method for metoprolol.  
The recovery and matrix effects of metoprolol and 
α-hydroxy metoprolol were similar in each sample 
analysis, which confirmed both compounds could be 
consistently quantified.  Metoprolol and α-hydroxy 
metoprolol in 10- and 100-fold diluted solutions with 
blank plasma met the acceptance criteria for dilution 
integrity.  Metoprolol and α-hydroxy metoprolol in 
sample extracts were confirmed to be stable for 72 hours 
when stored at 4°C in an autosampler, and those in 
plasma samples were stable at room temperature for 24 
hours.  Also, the stability for three freeze (−80°C) and 
thaw cycles was confirmed.  Metoprolol and α-hydroxy 
metoprolol standard solutions and internal standard 
solution were stable at -80°C for 150 days.  
 
Application of the developed analytical methods to 
clinical sample 
The developed analytical methods were applied to 
the measurement of 4 compounds and their metabolites 
in the samples obtained from a micro-dose clinical trial 
(15)
.  A mixture of these drugs was administered orally 
and plasma samples were collected for 0.5, 1, 2, 4, 8, and 
12 hours after dosing.  It was shown that lansoprazole 
and its metabolite, glibenclamide and warfarin, and 
metoprolol and its metabolite in human plasma are 
measurable by these methods.  Plasma concentrations 
of these compounds in one subject who was taken from 
micro-dose clinical trial are shown in Table VII. 




able to confirm the time-concentration profile of these 
drugs in plasma after administration, and confirmed they 






Intra-day reproducibility of lansoprazole in human plasma. 
Sample Concentration (pg/mL) 
No. 20  RE (%) 400  RE (%) 8000  RE (%) 
1 21.05  5.3  455.3  13.8  8708  8.9  
2 22.68  13.4  457.8  14.5  8527  6.6  
3 21.89  9.5  461.3  15.3  8831  10.4  
4 20.44  2.2  456.6  14.2  8547  6.8  
5 20.26  1.3  457.7  14.4  8733  9.2  
Mean 21.26  6.3  457.7  14.4  8669  8.4  
SD 1.02  - 2.2  - 129  - 
CV (%) 4.8  - 0.5  - 1.5  - 
- : Not calculated 
      
Table II 
Intra-day reproducibility of 5-hydroxy lansoprazole in human plasma. 
Sample Concentration (pg/mL) 
No. 20  RE (%) 400  RE (%) 8000  RE (%) 
1 20.55  2.8  386.3  -3.4  8078  1.0  
2 20.53  2.7  395.8  -1.1  8065  0.8  
3 21.51  7.6  416.8  4.2  8841  10.5  
4 19.76  -1.2  397.4  -0.7  7878  -1.5  
5 21.70  8.5  402.6  0.7  8225  2.8  
Mean 20.81  4.1  399.8  -0.1  8217  2.7  
SD 0.80  - 11.2  - 370  - 
CV (%) 3.8  - 2.8  - 4.5  - 
- : Not calculated 
      
Table III 
Intra-day reproducibility of glibenclamide in human plasma. 
Sample Concentration (pg/mL) 
No. 2  RE (%) 40  RE (%) 800  RE (%) 
1 1.786  -10.7  39.69  -0.8  808.9  1.1  
2 1.831  -8.5  38.86  -2.9  808.7  1.1  
3 1.702  -14.9  39.68  -0.8  888.4  11.1  
4 1.956  -2.2  41.32  3.3  761.1  -4.9  
5 1.983  -0.9  38.98  -2.6  813.0  1.6  
Mean 1.852  -7.4  39.71  -0.7  816.0  2.0  
SD 0.118  - 0.98  - 45.7  - 
CV (%) 6.4  - 2.5  - 5.6  - 
- : Not calculated 
















Intra-day reproducibility of warfarin in human plasma. 
Sample Concentration (pg/mL) 
No. 100  RE (%) 2000  RE (%) 40000  RE (%) 
1 101.0  1.0  2229  11.5  34670  -13.3  
2 102.5  2.5  2168  8.4  37940  -5.2  
3 94.67  -5.3  2230  11.5  39740  -0.7  
4 107.6  7.6  2078  3.9  34770  -13.1  
5 107.2  7.2  2100  5.0  34930  -12.7  
Mean 102.6  2.6  2161  8.1  36410  -9.0  
SD 5.3  - 71  - 2310  - 
CV (%) 5.2  - 3.3  - 6.3  - 
- : Not calculated 
      
Table V 
Intra-day reproducibility of metoprolol in human plasma. 
Sample Concentration (ng/mL) 
No. 0.2 RE (%) 2 RE (%) 40 RE (%) 
1 0.2103  5.2  1.959  -2.1  37.61  -6.0  
2 0.1764  -11.8  1.969  -1.6  39.40  -1.5  
3 0.2025  1.3  1.964  -1.8  34.36  -14.1  
4 0.2077  3.9  2.050  2.5  37.25  -6.9  
5 0.2002  0.1  1.820  -9.0  37.88  -5.3  
Mean 0.1994  -0.3  1.952  -2.4  37.30  -6.8  
SD 0.0135  - 0.083  - 1.84  - 
CV (%) 6.8  - 4.3  - 4.9  - 
-: Not calculated 
     
 
Table VI 
Intra-day reproducibility of metoprolol in human plasma. 
Sample Concentration (ng/mL) 
No. 0.2 RE (%) 2 RE (%) 40 RE (%) 
1 0.1997  -0.2  2.009  0.5  37.23  -6.9  
2 0.1733  -13.4  2.022  1.1  39.09  -2.3  
3 0.2122  6.1  1.960  -2.0  32.79  -18.0  
4 0.1925  -3.8  2.104  5.2  37.38  -6.6  
5 0.2189  9.5  2.027  1.4  37.52  -6.2  
Mean 0.1993  -0.4  2.024  1.2  36.80  -8.0  
SD 0.0178  - 0.052  - 2.36  - 
CV (%) 8.9  - 2.6  - 6.4  - 
-: Not calculated 
     
 
Table VII 
Concentrations of lansoprazole and its metabolite, glibenclamide and warfarin, and metoprolol and its metabolite 
in human plasma. 
Time (hour) 0.5 1 2 4 8 12 
Lansoprazol (pg/mL) ND ND 1758 311.7 17.84 ND 
5-Hydroxy lansoprazol (pg/mL) ND ND 249.2 42.04 ND ND 
Glibenclamide (pg/mL) 104.0  117.6 131.4 121.2 27.87 8.021 
Warfarin (pg/mL) 1602 947.2 711.5 616.9 341.6 331.8 
Metoprolol 0.4468 0.6700  0.2797 0.7443 0.4125 0.1357 
α-Hydroxy metprolol ND 0.2546 0.1037 0.1056 ND ND 











Figure 2.  Typical chromatograms of lansoprazole, 5-hydroxy lansoprazole, and internal standard. 
 
a) Blank sample of lansoprazole 
b) Blank sample of 5-hydroxy lansoprazole 
c) Blank sample of internal standard 
d) Calibration sample of lansoprazole 
e) Calibration sample of 5-hydroxy lansoprazole 














Figure 3.  Typical chromatograms of glibenclamide, warfarin, and internal standard. 
 
a) Blank sample of glibenclamide 
b) Blank sample of warfarin 
c) Blank sample of internal standard 
d) Calibration sample of glibenclamide 
e) Calibration sample of warfarin 
f) Calibration sample of internal standard 
 
Figure 4.  Typical chromatograms of metoprolol, α-hydroxy metoprolol, and internal standard. 
 
a) Blank sample of metoprolol 
b) Blank sample of α-hydroxy metoprolol 
c) Blank sample of internal standard 
d) Calibration sample of metoprolol 
e) Calibration sample of α-hydroxy metoprolol 
f) Calibration sample of internal standards 
 
Conclusion  
We have established high-sensitivity analytical 
methods for lansoprazole, glibenclamide, and warfarin, 
although we were not able to do so for metoprolol.  
These analytical methods could be used to analyze these 
drugs and metabolites in human plasma samples in 
micro-dose clinical trials and were confirmed as 
high-sensitivity methods indicated by the ability to detect 
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